Synopsys
SNPS
$422.48
-6.36%
Synopsys is the largest pure-play provider of electronic design automation (EDA) software and semiconductor intellectual property (IP), supplying the design, verification, and signoff tools that chipmakers and systems companies use to architect advanced silicon; it also sells design IP blocks and, following its acquisition of Ansys, simulation and multiphysics analysis software. The company sits at the chokepoint of the semiconductor value chain, functioning as a quasi-monopoly duopoly partner to Cadence, with high switching costs, subscription-like revenue, and a customer base spanning TSMC, Nvidia, Intel, and a growing roster of hyperscalers designing in-house accelerators. The current investor debate centers on whether Synopsys is a genuine AI infrastructure beneficiary — reinforced by a reported $2 billion Nvidia investment and strategic deals with TSMC, OpenAI, and Amazon — or whether the Ansys acquisition is masking weak organic growth, a tension visible in the stock's sharp drawdown through mid-2026 followed by a violent late-September/October recovery rally. Management's 2027 revenue target of roughly $11.2 billion, which exceeded analyst estimates, alongside raised guidance and a wave of analyst upgrades, has reframed the narrative toward AI-driven design demand and post-merger earnings power.…
SNPS
Synopsys
$422.48
Related headlines
Investment Opinion: Should I buy SNPS Today?
We rate Synopsys a Buy, anchored by its strong_buy consensus (mean rating 1.24) and an average analyst target of $583.99, implying 28.5% upside from $454.63. The core thesis is that Synopsys is a quasi-monopoly in EDA with recurring revenue and AI-driven demand, and the Ansys acquisition, while dilutive near-term, expands its simulation footprint and long-term earnings power. The recent pullback from $510 to $454.63 offers an entry point for long-term investors willing to tolerate integration risk.
The supporting evidence is compelling: revenue grew 42.37% YoY in Q3 2026 to $2.478 billion, trailing free cash flow is $2.79 billion, and the forward PE of 24.35x is below the typical 30–40x for high-quality software franchises. The gross margin of 76.98% and net margin of 18.89% reflect a premium business model, and the 2027 revenue target of $11.2 billion exceeded consensus. Analyst estimates for forward EPS of $33.51 and revenue of $16.30 billion underpin the optimistic outlook, and the stock's 20.12% one-month gain shows momentum is turning.
Key risks include integration friction that could delay margin recovery, organic growth remaining flattish, and valuation compression if earnings disappoint. The rating would upgrade to a strong buy if organic growth accelerates above 10% and operating margins recover above 20%, or downgrade to Hold if revenue growth decelerates below 5% or the 2027 target is cut. Relative to its history, the trailing PE of 55.82x is in the upper-middle of its range, but the forward PE of 24.35x suggests the stock is fairly valued to slightly undervalued on normalized earnings. We view the risk/reward as favorable for long-term investors.
Sign up to view all
SNPS 12-Month Price Forecast
We are bullish with medium confidence, balancing the strong analyst support and AI-driven growth potential against integration risks and margin compression. The stock's 20% one-month rally shows momentum, but the fade from $510 to $454.63 indicates near-term caution. We would upgrade to high confidence if organic growth accelerates and margins recover, and downgrade to neutral if the 2027 revenue target is questioned or integration issues emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Synopsys's 12-month outlook, with a consensus price target around $586.95 and implied upside of +38.9% versus the current price.
Average Target
$586.95
0 analysts
Implied Upside
+38.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$475 - $700
Analyst target range
Coverage is deep and overwhelmingly bullish: 25 analysts cover the stock with a consensus recommendation of "strong_buy" and a mean rating of 1.24 (where 1.0 is a strong buy), and the average target price of $583.99 implies roughly +28.5% upside from the current $454.63. Even the lowest target of $475.00 sits about 4.5% above the current price, meaning every published analyst target is above the market — a rare unanimity that signals the sell-side views the recent pullback as an opportunity rather than a deterioration. Consensus forward EPS of $33.51 and revenue of $16.30 billion underpin that optimism, and the bullish tilt is corroborated by a wave of upgrades: HSBC moved to Buy from Hold on September 25, Wells Fargo and Morgan Stanley both moved to Overweight from Equal Weight in early September, and Baird upgraded to Outperform from Neutral on August 27.
The target range of $475 to $700 is wide — a 47% spread from low to high — which signals meaningful disagreement about the magnitude of the AI and Ansys payoff even as directionally everyone is constructive. The $700 high target implicitly assumes multiple expansion on top of the raised 2027 revenue target, sustained AI-driven design demand from Nvidia, TSMC, OpenAI, and Amazon partnerships, and clean margin recovery toward historical levels; the $475 low target essentially prices in the current earnings trajectory with little credit for reacceleration, i.e., integration friction and modest organic growth. The clustering of upgrades around the August 27 Q3 beat and the October 1 guidance raise suggests estimate revisions are still trending upward, which historically supports further target increases; however, the stock's 12.8% single-day gap on October 1 means much of the near-term upside to consensus has already been captured, and the subsequent fade to $454.63 has reopened roughly 28% of headroom — a setup where conviction is high but the path likely depends on the next quarterly print validating the 2027 target.
Drowning in data?
Find the real signal!
Bulls vs Bears: SNPS Investment Factors
The bull case rests on Synopsys' dominant position in EDA, strong free cash flow, AI partnerships, and a raised 2027 revenue target that has sparked analyst upgrades and a 20% one-month rally. However, the bear case highlights weak organic growth masked by the Ansys acquisition, margin compression, and a relative performance lag versus the market. Currently, the bull evidence appears stronger given unanimous analyst targets above the current price, robust cash generation, and strategic AI tailwinds, but the most important tension is whether organic growth can reaccelerate to justify the premium valuation. If organic growth remains flattish, the stock could struggle to reach the high end of analyst targets; conversely, a clear reacceleration would validate the bull thesis.
Bullish
- Analyst unanimity with 28.5% upside: All 25 covering analysts have targets above the current $454.63 price, with a low of $475 and an average of $583.99, implying 28.5% upside. The consensus recommendation is 'strong_buy' with a mean rating of 1.24, and recent upgrades from HSBC, Wells Fargo, Morgan Stanley, and Baird reinforce the bullish tilt.
- Raised 2027 revenue target signals confidence: Management's 2027 revenue target of ~$11.2 billion exceeded analyst estimates, triggering a 12.8% single-day gap on October 1. This target, alongside raised guidance, reframes the narrative toward AI-driven design demand and post-merger earnings power.
- Strong free cash flow and balance sheet: Trailing free cash flow is $2.79 billion, with Q3 operating cash flow of $812.8 million against capex of just $66.6 million (12.2x coverage). Cash stands at $3.61 billion, and debt-to-equity is a manageable 0.505, providing flexibility for integration and growth.
- AI partnerships validate strategic position: A reported $2 billion Nvidia investment and strategic deals with TSMC, OpenAI, and Amazon underscore Synopsys' role as a critical enabler of AI chip design. These partnerships could drive sustained demand for EDA tools and IP as AI accelerators proliferate.
Bearish
- Organic growth masked by Ansys acquisition: Q3 2026 revenue grew 42.37% YoY to $2.478 billion, but sequential comparisons show a flattish organic base (Q1 $2.409B, Q2 $2.276B, Q3 $2.478B). Press commentary highlights weak organic growth being masked by the Ansys deal, raising questions about underlying demand.
- Margin compression from acquisition mix: Gross margin fell to 72.57% in Q3 2026 from 78.13% a year ago and 81.45% in Q1 2025, due to lower-margin Ansys mix and amortization. Operating margin of 14.43% remains far below the historical 23–27% profile, and interest expense of $133.2 million weighs on earnings.
- Relative performance lagging the market: The stock is up only 3.28% over the past year versus a 15.53% gain for the S&P 500, a relative strength deficit of -12.25 percentage points. It remains down 5.37% YTD and sits at roughly 52% of its 52-week range, indicating incomplete recovery.
- Integration and execution risks: The Ansys acquisition has depressed ROE to 4.70% and ROA to 1.35%, and interest coverage is thin at 2.68x. Integration costs and amortization of acquired intangibles could delay earnings normalization, and the wide analyst target range ($475–$700) signals disagreement on the payoff.
SNPS Technical Analysis
Synopsys is in a recovery phase within a broader range-bound consolidation: the stock is up just 3.28% over the past year versus a 15.53% gain for the S&P 500, a relative strength deficit of -12.25 percentage points, and it remains down 5.37% year-to-date. At $454.63, the shares sit at roughly 52% of the 52-week range of $362.55 to $539.48 — squarely mid-range, meaning neither momentum-chasing nor deep-value territory, but rather a stock that has repaired a severe drawdown without yet reclaiming its highs. The maximum drawdown of -31.21% over the period underscores how violent the spring-to-summer decline was, and the current positioning suggests the market is still adjudicating whether the bottom is in.
Short-term momentum is decisively positive and sharply divergent from the longer-term trend: the stock has gained 20.12% over the past month and 18.31% over three months, versus a 1.22% and 2.69% advance for SPY, producing relative strength readings of +18.90 and +15.62 points respectively. That one-month surge was punctuated by a single-session gap from $434.94 on September 30 to $490.54 on October 1 — a roughly 12.8% move tied to the raised 2027 revenue target — followed by a push to $509.99 on October 9 before a five-session fade to $454.63, including a -2.88% drop on the final day. This pattern — explosive catalyst-driven re-rating followed by partial retracement — suggests the move is real but that near-term buyers are taking profits into strength; the divergence between +20% one-month and +3% one-year performance signals a potential trend reversal still in need of confirmation rather than a completed breakout.
Key technical levels are well defined: support sits at the 52-week low of $362.55, with an intermediate shelf around $415–$425 where the stock consolidated in August and September, while resistance lies at the 52-week high of $539.48, with the October 9 intraday peak near $510 as the first hurdle. A decisive close above $510–$520 would confirm the reversal and open a path toward the highs, whereas a break below $425 would invalidate the October catalyst and refocus attention on the $362.55 floor. With a beta of 1.208, Synopsys is roughly 21% more volatile than the market — meaningful for position sizing, and consistent with the observed 31% peak-to-trough drawdown; the short ratio of 2.49 days indicates modest short interest and limited squeeze fuel, so the rally appears driven by genuine repositioning rather than a short covering spike.
Beta
1.21
1.21x market volatility
Max Drawdown
-31.2%
Largest decline past year
52-Week Range
$363-$539
Price range past year
Annual Return
-7.0%
Cumulative gain past year
| Period | SNPS Return | S&P 500 |
|---|---|---|
| 1m | +3.2% | -1.2% |
| 3m | +13.1% | +3.4% |
| 6m | -15.6% | +7.0% |
| 1y | -7.0% | +14.4% |
| ytd | -12.1% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SNPS Fundamental Analysis
Revenue is inflecting sharply upward, though largely through acquisition: fiscal Q3 2026 (quarter ended July 31, 2026) revenue reached $2.478 billion, up 42.37% year-over-year from $1.740 billion, but the sequential comparison to Q2's $2.276 billion and Q1's $2.409 billion shows a flattish organic base, consistent with press commentary that weak organic growth is being masked by the Ansys deal. The segment mix shows License and Maintenance at $1.003 billion, Technology Service at $809 million, and License at $665 million, with the recurring maintenance and service lines providing the durability that underpins the model. The trajectory — Q1 $2.409B, Q2 $2.276B, Q3 $2.478B — implies growth is lumpy and license-timing dependent rather than smoothly compounding, which is precisely why the raised 2027 target of ~$11.2 billion (versus consensus revenue of $16.30 billion for the forward period) matters as a credibility test for the AI-demand thesis.
Profitability is strong at the gross line but heavily burdened below it: gross margin was 72.57% in Q3 2026, down from 78.13% in the year-ago quarter and 81.45% in Q1 2025, reflecting the lower-margin Ansys mix and amortization of acquired intangibles. Q3 net income of $545.8 million (22.04% net margin) and EPS of $2.85 contrast starkly with Q2's $17.1 million net income (0.75% margin) and $0.09 EPS, a swing driven by a $217 million negative swing in other income/expense and interest expense of $133.2 million tied to acquisition debt. Operating margin of 14.43% in Q3 versus 10.38% in Q2 and 8.43% in Q1 shows sequential recovery, but the trailing operating margin of 12.97% and GAAP EPS of $0.018 remain far below the company's historical ~23–27% operating margin profile, signaling that integration costs and interest are the swing factor for earnings normalization.
Balance sheet and cash generation are the strongest part of the story: trailing free cash flow is $2.79 billion, Q3 operating cash flow was $812.8 million against capex of just $66.6 million (a 12.2x capex coverage ratio), and cash stood at $3.61 billion at quarter-end. Debt-to-equity is a manageable 0.505 with a current ratio of 1.615, and the Q1 2026 debt repayment of $3.45 billion alongside $2.01 billion of common stock issued shows active deleveraging and equity funding of the Ansys transaction. The weak spots are returns and coverage: ROE of 4.70% and ROA of 1.35% are depressed by the enlarged equity base and intangible-heavy assets, while interest coverage of 2.68x and cash-flow-to-debt of 0.075 are thin for an investment-grade software franchise — the company can fund growth internally on cash flow, but the balance sheet is no longer the fortress it was pre-deal.
Quarterly Revenue
$2.5B
2026-07
Revenue YoY Growth
+42.4%
YoY Comparison
Gross Margin
72.6%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SNPS Overvalued?
Because trailing net income is positive but distorted by acquisition accounting, the PE ratio is the appropriate lead metric, with PS as a cross-check: the trailing PE is 55.82x against a forward PE of 24.35x, an enormous 56% compression that implies the market expects earnings to more than double as Ansys synergies and interest costs normalize. The PS ratio of 10.30x and EV/Sales of 10.30x are more moderate for a high-margin software franchise, while EV/EBITDA of 33.63x and price-to-free-cash-flow of 47.87x confirm the stock is priced for substantial earnings recovery rather than current profitability. The gap between trailing and forward multiples is the single most important valuation fact here — it is either a credible roadmap to normalized earnings or a warning that consensus is extrapolating a recovery that integration risk could delay.
Relative to the software-infrastructure peer group, Synopsys screens as a premium asset on cash flow but not egregiously on sales: PS of 10.30x and EV/Sales of 10.30x sit at the high end of large-cap infrastructure software, while the 76.98% gross margin and 18.89% net margin justify a quality premium over the sector. The forward PE of 24.35x is actually below the typical 30–40x band for high-quality EDA/software franchises, suggesting that on normalized earnings the stock is not expensive — the premium is concentrated in trailing metrics inflated by deal-related charges. The PEG ratio of -1.24 is not meaningful given the depressed trailing earnings base, and the negative reading should be treated as a data artifact rather than a valuation signal.
Historically, Synopsys has traded in a wide PE band: 46.9x at fiscal Q4 2025, 34.1x at Q3 2026, and a spike to 1,340x in Q2 2026 when earnings briefly collapsed — versus a pre-deal range of roughly 37–73x across 2021–2024. The current 55.82x trailing PE sits in the upper-middle of that historical band, while the PS ratio of 10.30x is dramatically below the 30–58x readings recorded through 2025–2026, a distortion caused by the post-Ansys revenue base expanding faster than the market cap. The takeaway is that the stock is neither at a historical valuation extreme nor cheap: the market is pricing in successful integration and AI-driven reacceleration, leaving limited margin for error if organic growth disappoints.
PE
55.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 18x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are centered on the Ansys integration and its impact on margins and returns. Gross margin has compressed to 72.57% from 81.45% in Q1 2025, and operating margin of 14.43% is well below the historical 23–27% range, reflecting lower-margin Ansys mix and amortization. Interest expense of $133.2 million and a thin interest coverage ratio of 2.68x add pressure, while ROE of 4.70% and ROA of 1.35% are depressed. The company's debt-to-equity of 0.505 is manageable, but the balance sheet is no longer a fortress, and free cash flow of $2.79 billion must support integration costs and debt service.
Market and competitive risks include valuation compression if organic growth disappoints. The stock trades at a PS ratio of 10.30x and EV/EBITDA of 33.63x, pricing in a strong recovery. With a beta of 1.208, Synopsys is 21% more volatile than the market, and its 31.21% max drawdown over the past year illustrates sensitivity to sentiment. Competitive threats from Cadence and emerging EDA tools could pressure pricing, while regulatory scrutiny of the Ansys deal or AI partnerships may pose headwinds. Recent news highlights the disconnect between weak organic growth and climbing analyst targets, a tension that could trigger volatility if not resolved.
A worst-case scenario would involve a delay in Ansys synergies, organic growth stalling, and a market rotation away from high-multiple software stocks. In such a scenario, the stock could retest its 52-week low of $362.55, representing a 20.3% decline from the current $454.63. If analyst bear-case targets near $475 are breached and sentiment sours, the downside could extend to the $362.55 level, implying a loss of approximately 20% from current prices. A more severe outcome, such as integration missteps or a recession, could push the stock below the 52-week low, but that is not our base case.
FAQ
The most severe risk is integration and execution risk from the Ansys acquisition, which has already compressed gross margins to 72.57% from 81.45% and kept operating margins at 14.43% versus historical 23-27%. Second, organic growth is weak, with sequential revenue flat around $2.3-2.5 billion, and if it fails to reaccelerate, the premium valuation could compress. Third, financial risks include interest expense of $133.2 million and thin interest coverage of 2.68x, which could strain if earnings disappoint. Fourth, market risk is elevated with a beta of 1.208 and a 31.21% max drawdown in the past year, making the stock sensitive to sector rotations and macro headwinds.
Our 12-month forecast has a base case (50% probability) of $475-$584, aligned with the analyst average target of $583.99, assuming steady integration and mid-single-digit organic growth. The bull case (30% probability) targets $584-$700, driven by successful Ansys synergies, AI design wins, and margin recovery. The bear case (20% probability) sees $362-$475, reflecting integration delays and organic growth stagnation. The most likely scenario is the base case, with the key assumption that operating margins improve to 16-18% and revenue meets the 2027 target of $11.2 billion. The wide target range reflects disagreement on the pace of recovery.
SNPS appears fairly valued to slightly undervalued on a forward basis. The trailing PE of 55.82x is elevated but distorted by acquisition accounting, while the forward PE of 24.35x is below the typical 30-40x range for high-quality EDA/software peers. The PS ratio of 10.30x is at the high end of large-cap infrastructure software but justified by 76.98% gross margins and 18.89% net margins. Compared to its own history, the trailing PE is in the upper-middle of its 37-73x range, but the PS ratio is well below the 30-58x readings of 2025-2026 due to the expanded revenue base. The market is pricing in successful integration and earnings recovery, leaving limited margin for error.
From a risk/reward perspective, SNPS offers a favorable setup with 28.5% upside to the average analyst target of $583.99 and a strong_buy consensus. The stock trades at a forward PE of 24.35x, which is reasonable for a high-quality franchise with 42% revenue growth and 76.98% gross margins. However, the biggest downside risk is integration friction from the Ansys acquisition, which has compressed margins and could delay earnings recovery. For long-term investors with a 2-3 year horizon, the current price near $454.63 represents a good entry point, especially given the AI partnerships and raised 2027 target. Short-term traders should be cautious due to the recent 20% rally and potential for profit-taking.
SNPS is best suited for long-term investment given its quasi-monopoly in EDA, recurring revenue, and strategic AI partnerships. The stock's beta of 1.208 and 31.21% max drawdown indicate high volatility, making it less appropriate for short-term trading unless timed around catalysts. The lack of a dividend (payout ratio 0%) means returns depend on capital appreciation, which requires patience through integration. Earnings visibility is improving with the raised 2027 target, but near-term fluctuations are likely. We recommend a minimum holding period of 2-3 years to allow Ansys synergies to materialize and organic growth to reaccelerate.
